DCE-MRI与DWI评估肌层浸润性膀胱癌新辅助化疗后病理反应的系统评价与荟萃分析
该系统评价与荟萃分析纳入11项研究,评估DCE-MRI与DWI预测肌层浸润性膀胱癌新辅助化疗后病理反应的诊断效能。DCE-MRI汇总敏感度0.88、特异度0.88、AUC 0.93;DWI汇总敏感度0.83、特异度0.88、AUC 0.92,两者敏感度、特异度及AUC均无显著差异,但结论基于间接比较。
要点
- DCE-MRI预测病理反应汇总敏感度0.88、特异度0.88、AUC 0.93。
- DWI预测病理反应汇总敏感度0.83、特异度0.88、AUC 0.92。
- DWI与DCE-MRI的敏感度、特异度及AUC均无显著差异,但为间接比较。
核心结论
- DCE-MRI与DWI对预测MIBC新辅助化疗后病理反应均具有高诊断效能,DWI可能是DCE-MRI的潜在替代方法,但结果基于间接比较,应用时需谨慎。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Cochrane Library、Web of Science和EMBASE数据库,纳入11项研究,其中6项仅行DCE-MRI检查、4项仅行DWI检查、1项同时行两者检查,采用QUADAS-2工具评估研究质量。
诊断标准与关键数值
- DCE-MRI汇总敏感度0.88(95%CI 0.78-0.93)、特异度0.88(95%CI 0.67-0.96)、阳性似然比7.4(95%CI 2.3-24.2)、阴性似然比0.14(95%CI 0.07-0.27)、诊断比值比53(95%CI 10-288)、SROC曲线AUC 0.93(95%CI 0.91-0.95);DWI汇总敏感度0.83(95%CI 0.75-0.88)、特异度0.88(95%CI 0.81-0.93)、阳性似然比7.1(95%CI 4.3-11.7)、阴性似然比0.20(95%CI 0.14-0.28)、诊断比值比36(95%CI 18-73)、SROC曲线AUC 0.92(95%CI 0.89-0.94)。
临床应用与阅片要点
- 作者认为DWI可能是DCE-MRI的潜在替代方法,但强调结果基于间接比较,应用时需谨慎。
局限性
- 结果基于间接比较,应用时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this meta-analysis was to determine the value of dynamic contrast-enhanced-MRI (DCE-MRI) and diffusion-weighted imaging (DWI) in evaluating the pathological response of muscle invasive bladder cancer (MIBC) to neoadjuvant chemotherapy (NAC), and further indirectly compare the diagnostic performance of DCE-MRI and DWI.
METHODS: Literatures associated to DCE-MRI and DWI in the evaluation of pathological response of MIBC to NAC were searched from PubMed, Cochrane Library, web of science, and EMBASE databases. The quality assessment of diagnostic accuracy studies 2 tool was used to assess the quality of studies. Pooled sensitivity (SE), specificity (SP), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curves (AUC) with their 95% confidence intervals (CIs) were calculated to evaluate the diagnostic performance of DCE-MRI and DWI in predicting the pathological response to NAC in patients with MIBC.
RESULTS: There were 11 studies involved, 6 of which only underwent DCE- MRI examination, 4 of which only underwent DWI examination, and 1 of which underwent both DCE- MRI and DWI examination. The pooled SE, SP, PLR, NLR, DOR of DCE-MRI were 0.88 (95% CI: 0.78-0.93), 0.88 (95% CI: 0.67-0.96), 7.4 (95% CI: 2.3-24.2), 0.14 (95% CI: 0.07-0.27), and 53 (95% CI: 10-288), respectively. The pooled SE, SP, PLR, NLR, DOR of DWI were 0.83 (95% CI: 0.75-0.88), 0.88 (95% CI: 0.81-0.93), 7.1 (95% CI: 4.3-11.7), 0.20 (95% CI: 0.14-0.28), and 36 (95% CI:18-73), respectively. The AUCs of SROC curve for DCE-MRI and DWI were 0.93 (95% CI: 0.91-0.95) and 0.92 (95% CI: 0.89-0.94), respectively. There were no significant differences between DWI and DCE-MRI for SE, SP, and AUC.
CONCLUSION: This meta-analysis demonstrated high diagnostic performance of both DCE-MRI and DWI in predicting the pathological response to NAC in MIBC. DWI might be a potential substitute for DCE-MRI, with no significant difference in diagnostic performance between the two. However, caution should be taken when applying our results, as our results were based on indirect comparison.
ADVANCES IN KNOWLEDGE: No previous studies have comprehensively analysed the value of DCE-MRI and DWI in evaluating the pathological response to NAC in MIBC. According to the current study, both DCE-MRI and DWI yielded high diagnostic performance, with the AUCs of 0.93 and 0.92, respectively. Indirect comparison no significant difference in the diagnostic performanceof DCE-MRI and DWI.
引用
- Zong R, Ma X, Shi Y, et al. The assessment of pathological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review and meta-analysis. Br J Radiol. 2023. PMID: 37660472. doi:10.1259/bjr.20230239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。